NP 000888Alternative Names: NP-000888
Latest Information Update: 28 Dec 2016
At a glance
- Originator Galderma
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Psoriasis
Most Recent Events
- 28 Dec 2016 Preclinical trials in Psoriasis in Taiwan (Topical) (NCT02995473) before December 2016
- 01 Dec 2016 Galderma plans a phase II trial for Plaque and Nail Psoriasis in Taiwan (NCT02995473)